Joyo Capital Partners
VC Fund
Joyo Capital Partners is a VC fund focused on Medical and Artificial Intelligence. Venture capital 100% owned by Joyo Bank
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Joyo Capital Partners invests in
Stages Joyo Capital Partners invests in
Countries Joyo Capital Partners invests in
Round sizes
Round size
- Series A
- $1.7M–$12M
- Series B
- $3.6M–$16M
Investment Focus
Industry
- Medical 3 (27%)
- Artificial Intelligence 3 (27%)
- Aerospace 2 (18%)
- Health Care 2 (18%)
- Therapeutics 2 (18%)
Stage
- Series A 7 (64%)
- Series B 3 (27%)
- Series D 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SiccaNova Therapeutics is a Japanese biopharmaceutical company dedicated to treating sicca (dryness) related medical conditions. The company’s lead drug candidate, XF8302, is a novel, small-molecule M3 muscarine receptor Positive Allosteric Modulator (M3 PAM). Developed initially for dry mouth in Sjögren’s syndrome patients, the drug enhancesnatural acetylcholine signaling to stimulate salivation without the systemic side effects common in traditional agonists. | $7.9M / Series A / Sep 03, 2026 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.6M / Series B / Oct 07, 2025 | ||
| SAKANA Dream develops unique farmed fish species by leveraging an innovative breeding technology "Surrogate Broodstock Technology". The company selects outstanding fish from over 4,000 species living in Japan and produces remarkable hybrid fish which have both great taste and high productivity. | $6.7M / Series A / Sep 02, 2025 | ||
| Linea Innovations is an energy production company that develops commercial fusion reactors with advanced fuel technology. | $12.3M / Series A / Jun 02, 2025 | ||
| Alpha Fusion produces astatine based radiopharmaceuticals for targeted alpha therapy. | $6.9M / Series B / Oct 08, 2024 | ||
| Office de Yasai is an online platform that enables users to order and get vegetables delivered to their offices. The platform’s operations are based in Tokyo, Japan. | $7.4M / Series D / Aug 20, 2024 | ||
| Pale Blue provides a variety of water propulsion systems with high-performance, affordable price, short-lead time, and reliability. | $16.1M / Series B / Jun 04, 2024 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3M / Series A / May 08, 2024 | ||
| LIGHTz delivers a technology transfer and information exchange platform leveraging AI. | $5.7M / Series A / Mar 26, 2024 | ||
| Tenchijin is optimiz human civilization using space big data. | $1.7M / Series A / Jan 31, 2024 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Joyo Capital Partners invest in?
Joyo Capital Partners invests primarily in Medical, Artificial Intelligence and Aerospace startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Joyo Capital Partners's check size?
Joyo Capital Partners typically joins rounds of $1.7M–$12M at Series A and $3.6M–$16M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Joyo Capital Partners participates in.
When did Joyo Capital Partners last invest?
The most recent investment recorded for Joyo Capital Partners closed in Sep 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
